Current filters:

Merck KGaADiabetes

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure


Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

Merck KGaA links with Bristol-Myers for Glucophage promotion in China


German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

Merck Serono collaborates with Neopharma for production in UAE


Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Germany, and Unite Arab Emirates drug manufacturer…

DiabetesEuthyroxGlucophageGlucophage XRMerck KGaAMerck SeronoNeopharmaPharmaceuticalProductionRest of the WorldWomen's Health

Galapagos expands metabolic disease with Merck & Co; will now get more than 400 million euros


Belgian firm Galapagos has expanded its global strategic alliance in metabolic diseases with an affiliate…

Cardio-vascularDiabetesEuropeLicensingMerck KGaAMetabolicsNorth AmericaPharmaceutical

AstraZeneca’s potential blockbuster diabetes drug Onglyza approved by EC


The European Commission has granted marketing authorization for Anglo-Swedish drug major AstraZeneca…

AstraZenecaBristol-Myers SquibbDiabetesEuropeJanuviaMerck KGaANystatinOralPharmaceuticalsitagliptin

Back to top